1. Home
  2. BHVN vs GDS Comparison

BHVN vs GDS Comparison

Compare BHVN & GDS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • BHVN
  • GDS
  • Stock Information
  • Founded
  • BHVN 2013
  • GDS 2001
  • Country
  • BHVN United States
  • GDS China
  • Employees
  • BHVN N/A
  • GDS N/A
  • Industry
  • BHVN Biotechnology: Pharmaceutical Preparations
  • GDS Computer Software: Programming Data Processing
  • Sector
  • BHVN Health Care
  • GDS Technology
  • Exchange
  • BHVN Nasdaq
  • GDS Nasdaq
  • Market Cap
  • BHVN 3.6B
  • GDS 3.8B
  • IPO Year
  • BHVN 2017
  • GDS 2016
  • Fundamental
  • Price
  • BHVN $39.17
  • GDS $21.28
  • Analyst Decision
  • BHVN Strong Buy
  • GDS Buy
  • Analyst Count
  • BHVN 13
  • GDS 3
  • Target Price
  • BHVN $63.00
  • GDS $18.47
  • AVG Volume (30 Days)
  • BHVN 1.2M
  • GDS 1.4M
  • Earning Date
  • BHVN 02-27-2025
  • GDS 11-19-2024
  • Dividend Yield
  • BHVN N/A
  • GDS N/A
  • EPS Growth
  • BHVN N/A
  • GDS N/A
  • EPS
  • BHVN N/A
  • GDS N/A
  • Revenue
  • BHVN N/A
  • GDS $1,564,750,016.00
  • Revenue This Year
  • BHVN N/A
  • GDS $18.41
  • Revenue Next Year
  • BHVN $197.13
  • GDS $18.73
  • P/E Ratio
  • BHVN N/A
  • GDS N/A
  • Revenue Growth
  • BHVN N/A
  • GDS 11.95
  • 52 Week Low
  • BHVN $26.80
  • GDS $5.01
  • 52 Week High
  • BHVN $62.21
  • GDS $29.17
  • Technical
  • Relative Strength Index (RSI)
  • BHVN 51.03
  • GDS 46.92
  • Support Level
  • BHVN $35.01
  • GDS $21.15
  • Resistance Level
  • BHVN $39.36
  • GDS $24.08
  • Average True Range (ATR)
  • BHVN 2.07
  • GDS 1.68
  • MACD
  • BHVN 0.50
  • GDS -0.32
  • Stochastic Oscillator
  • BHVN 77.83
  • GDS 6.73

About BHVN Biohaven Ltd.

Biohaven Ltd is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of life-changing treatments in key therapeutic areas, including immunology, neuroscience, and oncology. Its product pipeline includes Glutamate, Myostatin, Ion channels, Inflammation & Immunology, and Oncology. Its products target diseases such as neuromuscular and metabolic diseases, antibody-drug conjugates for cancer, obsessive-compulsive disorder, and others.

About GDS GDS Holdings Limited ADS

GDS Holdings started as an IT service provider in 2001 then moved to the data center business with its first self-developed data center opening in 2010. The company now develops and operates data centers in China and also builds, operates and transfers data centers for other clients. It offers colocation and managed services and mainly targets hyperscale cloud service customers who take large areas of its data centers or even whole data centers under long-term contracts. It has aggressively raised capital over the past four years for expansion. Its data centers are located predominantly in and around the Tier 1 cities in China and it has also started an expanding into Southeast Asia. GDS listed on the Nasdaq in 2016 and completed a secondary listing in Hong Kong in 2020.

Share on Social Networks: